A single injection of the tyrosine kinase inhibitor hydrogel has demonstrated superiority to aflibercept 2 mg in maintaining visual acuity and providing higher rescue-free rates through 1 year in ...

– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients treated with the gene therapy maintained visual ...

EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (FDMT) (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched position in wet age-related macular degeneration (AMD) with investigational ...

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...